1 completed, 1 unknown. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Galactose Single Point (GSP), Residual Liver Function: new trials by email Literature Review of Galactose Single Point (GSP), Residual Liver Function trials Research Report on Galactose Single Point (GSP), Residual Liver Function
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®) G.S.P. Oral Solution 400 mg/ml - Galactose Single Point (GSP), Residual Liver Function | Phase 3 | Unknown | Richever Enterprise Co., Ltd. | 200 | 2013-09-09 | 2018-03-07 |
| GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours. - Galactose Single Point (GSP), Residual Liver Function | Phase 1 / Phase 2 | Completed | National Defense Medical Center, Taiwan | 210 | 2007-07-05 | 2020-09-14 |
Bone Diseases (2) · Bone Diseases, Metabolic (2) · Calcium Metabolism Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Metabolic Diseases (2) · Metabolism, Inborn Errors (2) · Metal Metabolism, Inborn Errors (2) · Musculoskeletal Diseases (2) · Nutritional and Metabolic Diseases (2)
National Defense Medical Center, Taiwan (1) · Richever Enterprise Co., Ltd. (1)